Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of EBITDA readings, the most recent being $153.6 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 62.71% to $153.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $485.9 million, a 42.87% increase, with the full-year FY2025 number at $485.9 million, up 42.87% from a year prior.
  • EBITDA hit $153.6 million in Q4 2025 for Neurocrine Biosciences, down from $210.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $210.2 million in Q3 2025 to a low of -$71.4 million in Q1 2023.
  • Median EBITDA over the past 5 years was $65.4 million (2022), compared with a mean of $66.2 million.
  • Biggest five-year swings in EBITDA: soared 1111.7% in 2022 and later tumbled 1233.33% in 2023.
  • Neurocrine Biosciences' EBITDA stood at -$9.4 million in 2021, then soared by 1111.7% to $95.1 million in 2022, then surged by 64.46% to $156.4 million in 2023, then plummeted by 39.64% to $94.4 million in 2024, then surged by 62.71% to $153.6 million in 2025.
  • The last three reported values for EBITDA were $153.6 million (Q4 2025), $210.2 million (Q3 2025), and $111.0 million (Q2 2025) per Business Quant data.